Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
There is lack of consensus on the prognostic value of received high dose intensity in osteosarcoma survivorship. Many studies have not shown a clear survival benefit when dose intensity is increased. The aim of this study is to go beyond chemotherapy intensification by arm-wide escalation of intended dose and/or compression of treatment schedule, while conversely addressing the relationship between treatment intensity and survival at the patient level. The study focusses on the difference in outcome results, based on a novel, progressively more individualised approach to dose intensity.
A retrospective analysis of data from MRC BO06/EORTC 80931 randomised controlled trial for treatment of osteosarcoma was conducted. Three types of post hoc patient groups are formed using the intended regimen: the individually achieved cumulative dose and time on treatment, and the increase of individual cumulative dose over time. Event-free survival is investigated and compared in these three stratifications.
The strata of intended regimen and achieved treatment yields equivalent results. Received cumulative dose over time produces groups with evident different survivorship characteristics. In particular, it highlights a group of patients with an estimated 3-year event-free survival much larger (more than 10%) than other patient groups. This group mostly contains patients randomised to an intensified regimen. In addition, adverse events reported by that group show the presence of increased preoperative myelotoxicity.
The manuscript shows the benefits of analyzing studies by using longitudinal data, e.g. recorded per cycle. This has impact on the drafting of future trials by showing why such a level of detail is needed for both treatment and adverse event data. The novel method proposed, based on cumulative dose received over time, shows that longitudinal treatment data might be used to link survival outcome with drug metabolism. This is particularly valuable when pharmacogenetics data for metabolism of cytotoxic agents are not collected.
Citron ML (2004) Dose density in adjuvant chemotherapy for breast cancer. Cancer Investig 22(4):555–568 CrossRef
Wildiers H, Reiser M (2001) Relative dose intensity of chemotherapy and its impact on outcomes in patients with early breast cancer or aggressive lymphoma. Crit Rev Oncol Hematol 77(3):221–240 CrossRef
Yuan JQ, Wang SM, Tang LL, Mao J, Wu YH, Hai J et al (2015) Relative dose intensity and therapy efficacy in different breast cancer molecular subtypes: a retrospective study of early stage breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat 151(2):405–413 CrossRefPubMed
Yabusaki N, Fujii T, Yamada S, Murotani K, Sugimoto H, Kanda M et al. The significance of relative dose intensity in adjuvant chemotherapy of pancreatic ductal adenocarcinoma—including the analysis of clinicopathological factors influencing relative dose intensity. Medicine 2016;95(29):e4282 CrossRefPubMedPubMedCentral
Lewis IJ, Nooij MA, Whelan J, Sydes MR, Grimer R, Hogendoorn PC et al (2007) Improvement in histologic response but not survival in osteosarcoma patients treated with intensified chemotherapy: a randomized phase III trial of the European Osteosarcoma Intergroup. J Natl Cancer Inst 99(2):112–128 CrossRefPubMed
Marina N, Bielack S, Whelan J, Smeland S, Krailo M, Sydes MR et al (2009) International collaboration is feasible in trials for rare conditions: the EURAMOS experience. In: Jaffe N, Bruland OS, Bielack S (eds) Pediatric and adolescent osteosarcoma. Springer, Boston, pp 339–353 CrossRef
Marina NM, Smeland S, Bielack SS, Bernstein M, Jovic G, Krailo MD et al (2016) Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol 17(10):1396–1408 CrossRefPubMedPubMedCentral
Lancia C, Anninga J, Spitoni C, Sydes MR, Whelan J, Hogendoorn PCW, Gelderblom AJ, Fiocco M (2018) A method to measure the mismatch between target and achieved received dose intensity of chemotherapy in cancer studies: the application to osteosarcoma randomised trial MRC-BO06. BMJ Open (Accepted)
McKinney W. Data structures for statistical computing in Python. In: Proceedings of the 9th Python in science conference; 2010 Jun 28, Austin, TX, pp 51–56
Pedregosa F, Varoquaux G, Gramfort A, Michel V, Thirion B, Grisel O et al (2011) Scikit-learn: machine learning in Python. J Mach Learn Res 12(Oct):2825–2830
Davidson-Pilon C, Kalderstam J, Kuhn B, Fiore-Gartland A, Parij A, Stark K et al (2018) Lifelines. version 0.11.1. https://github.com/CamDavidsonPilon/lifelines/. Accessed 1 Feb 2019
Kanekiyo S, Hazama S, Kondo H, Nagashima A, Eto R, Yoshida S et al (2013) UDP-glucuronosyltransferase (UGT) 1A1* 28 polymorphism-directed phase II study of irinotecan with 5′-deoxy-5-fluorouridine (5′-DFUR) for metastatic colorectal cancer. Anticancer Res 33(8):3423–3430 PubMed
McTiernan A, Jinks RC, Sydes MR, Uscinska B, Hook JM, van Glabbeke M et al (2012) Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European Osteosarcoma Intergroup. Eur J Cancer 48(5):703–712 CrossRefPubMedPubMedCentral
- A novel method to address the association between received dose intensity and survival outcome: benefits of approaching treatment intensification at a more individualised level in a trial of the European Osteosarcoma Intergroup
Jakob K. Anninga
Matthew R. Sydes
Pancras C. W. Hogendoorn
- Springer Berlin Heidelberg
Neu im Fachgebiet Onkologie
Mail Icon II